Cargando…
Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study
BACKGROUND: This study compared the long-term efficacy of different durations of adjuvant chemotherapy for patients with gastric cancer after radical gastrectomy with D2 lymphadenectomy. METHODS: We retrospectively identified 428 patients with stage II–III gastric cancer who underwent D2 gastrectomy...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406722/ https://www.ncbi.nlm.nih.gov/pubmed/34461860 http://dx.doi.org/10.1186/s12885-021-08717-4 |
_version_ | 1783746545599905792 |
---|---|
author | Chen, Lei Zhang, Chenghai Yao, Zhendan Cui, Ming Xing, Jiadi Yang, Hong Zhang, Nan Liu, Maoxing Xu, Kai Tan, Fei Li, Yuzhe Jiang, Beihai Su, Xiangqian |
author_facet | Chen, Lei Zhang, Chenghai Yao, Zhendan Cui, Ming Xing, Jiadi Yang, Hong Zhang, Nan Liu, Maoxing Xu, Kai Tan, Fei Li, Yuzhe Jiang, Beihai Su, Xiangqian |
author_sort | Chen, Lei |
collection | PubMed |
description | BACKGROUND: This study compared the long-term efficacy of different durations of adjuvant chemotherapy for patients with gastric cancer after radical gastrectomy with D2 lymphadenectomy. METHODS: We retrospectively identified 428 patients with stage II–III gastric cancer who underwent D2 gastrectomy between 2009 and 2016. Patients were divided into four groups according to the duration of adjuvant chemotherapy, including 0 week (no adjuvant, group A), 20 to 24 weeks (completed 7–8 cycles every 3 weeks or 10–12 cycles every 2 weeks, group B), and 12 to18 weeks (completed 4–6 cycles every 3 weeks or 6–9 cycles every 2 weeks, group C), and less than 12 weeks (received up to 3 cycles every 3 weeks or 5 cycles every 2 weeks, group D). The chemotherapy regimens included XELOX, SOX, and FOLFOX. 5-year overall survival (OS) and disease-free survival (DFS) were analyzed. RESULTS: The 5-year OS rates for groups A, B, C, and D were 52.3, 73.7, 72.0, and 53.3%, respectively, and the 5-year DFS rates were 50.0, 68.0, 65.4, and 50.0%, respectively. OS and DFS were higher in group B than in groups A and D. Similarly, patients in group C were more likely to have higher OS and DFS than those in groups A and D. Meanwhile, there were no significant differences in OS and DFS between groups B and C. The multivariate analysis confirmed with high statistical significance the efficacy of complete courses of adjuvant chemotherapy, and, among them, the similar impact of 4–6/6–9 and 7–8/10–12 cycles, resulting in similar HRs vs Group A (0.52 and 0.42, respectively). CONCLUSIONS: To reduce toxicity and maintain efficacy, XELOX or SOX chemotherapy regimens administered for 4–6 cycles every 3 weeks or FOLFOX regimen for 6–9 cycles every 2 weeks might be a favorable option for patients with stage II–III gastric cancer after D2 gastrectomy. Prospective multicenter clinical trials with adequate sample sizes are necessary to verify these findings. |
format | Online Article Text |
id | pubmed-8406722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84067222021-08-31 Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study Chen, Lei Zhang, Chenghai Yao, Zhendan Cui, Ming Xing, Jiadi Yang, Hong Zhang, Nan Liu, Maoxing Xu, Kai Tan, Fei Li, Yuzhe Jiang, Beihai Su, Xiangqian BMC Cancer Research Article BACKGROUND: This study compared the long-term efficacy of different durations of adjuvant chemotherapy for patients with gastric cancer after radical gastrectomy with D2 lymphadenectomy. METHODS: We retrospectively identified 428 patients with stage II–III gastric cancer who underwent D2 gastrectomy between 2009 and 2016. Patients were divided into four groups according to the duration of adjuvant chemotherapy, including 0 week (no adjuvant, group A), 20 to 24 weeks (completed 7–8 cycles every 3 weeks or 10–12 cycles every 2 weeks, group B), and 12 to18 weeks (completed 4–6 cycles every 3 weeks or 6–9 cycles every 2 weeks, group C), and less than 12 weeks (received up to 3 cycles every 3 weeks or 5 cycles every 2 weeks, group D). The chemotherapy regimens included XELOX, SOX, and FOLFOX. 5-year overall survival (OS) and disease-free survival (DFS) were analyzed. RESULTS: The 5-year OS rates for groups A, B, C, and D were 52.3, 73.7, 72.0, and 53.3%, respectively, and the 5-year DFS rates were 50.0, 68.0, 65.4, and 50.0%, respectively. OS and DFS were higher in group B than in groups A and D. Similarly, patients in group C were more likely to have higher OS and DFS than those in groups A and D. Meanwhile, there were no significant differences in OS and DFS between groups B and C. The multivariate analysis confirmed with high statistical significance the efficacy of complete courses of adjuvant chemotherapy, and, among them, the similar impact of 4–6/6–9 and 7–8/10–12 cycles, resulting in similar HRs vs Group A (0.52 and 0.42, respectively). CONCLUSIONS: To reduce toxicity and maintain efficacy, XELOX or SOX chemotherapy regimens administered for 4–6 cycles every 3 weeks or FOLFOX regimen for 6–9 cycles every 2 weeks might be a favorable option for patients with stage II–III gastric cancer after D2 gastrectomy. Prospective multicenter clinical trials with adequate sample sizes are necessary to verify these findings. BioMed Central 2021-08-30 /pmc/articles/PMC8406722/ /pubmed/34461860 http://dx.doi.org/10.1186/s12885-021-08717-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Chen, Lei Zhang, Chenghai Yao, Zhendan Cui, Ming Xing, Jiadi Yang, Hong Zhang, Nan Liu, Maoxing Xu, Kai Tan, Fei Li, Yuzhe Jiang, Beihai Su, Xiangqian Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study |
title | Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study |
title_full | Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study |
title_fullStr | Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study |
title_full_unstemmed | Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study |
title_short | Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study |
title_sort | adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with d2 lymphadenectomy: a retrospective control study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406722/ https://www.ncbi.nlm.nih.gov/pubmed/34461860 http://dx.doi.org/10.1186/s12885-021-08717-4 |
work_keys_str_mv | AT chenlei adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT zhangchenghai adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT yaozhendan adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT cuiming adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT xingjiadi adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT yanghong adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT zhangnan adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT liumaoxing adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT xukai adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT tanfei adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT liyuzhe adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT jiangbeihai adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy AT suxiangqian adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy |